Nu Skin Enterprises Reports Third-Quarter 2016 Results
"We are pleased that we exceeded guidance and posted year-over-year growth during the quarter," said
Regional Results
The company's regional revenue results for the three-month periods ended
2016 |
2015 |
% |
Constant |
|||||
Greater China |
$ 216,460 |
$ 188,669 |
15% |
20% |
||||
North Asia |
208,677 |
167,748 |
24% |
14% |
||||
South Asia/Pacific |
70,867 |
108,857 |
(35%) |
(36%) |
||||
Americas |
71,250 |
70,775 |
1% |
3% |
||||
EMEA |
36,908 |
35,259 |
5% |
5% |
||||
Total |
$ 604,162 |
$ 571,308 |
6% |
4% |
The company's regional revenue results for the nine-month periods ended
2016 |
2015 |
% |
Constant |
|||||
Greater China |
$ 611,887 |
$ 576,172 |
6% |
11% |
||||
North Asia |
525,771 |
512,757 |
3% |
---* |
||||
South Asia/Pacific |
226,742 |
247,697 |
(8%) |
(5%) |
||||
Americas |
204,882 |
234,115 |
(12%) |
(8%) |
||||
EMEA |
107,186 |
104,108 |
3% |
4% |
||||
Total |
$ 1,676,468 |
$ 1,674,849 |
---* |
2% |
*Less than a 1% change. |
The Company's regional actives and sales leaders statistics are presented in the following table.
As of September 30, 2016 |
As of September 30, 2015 |
% Increase (Decrease) |
||||||||||||
Actives |
Sales |
Actives |
Sales |
Actives |
Sales |
|||||||||
Greater China |
257,000 |
30,617 |
211,000 |
25,044 |
22% |
22% |
||||||||
North Asia |
334,000 |
18,688 |
374,000 |
18,038 |
(11%) |
4% |
||||||||
South Asia/Pacific |
116,000 |
7,213 |
120,000 |
9,925 |
(3%) |
(27%) |
||||||||
Americas |
171,000 |
6,660 |
178,000 |
7,962 |
(4%) |
(16%) |
||||||||
EMEA |
121,000 |
4,104 |
110,000 |
4,120 |
10% |
---* |
||||||||
Total |
999,000 |
67,282 |
993,000 |
65,089 |
1% |
3% |
||||||||
*Less than a 1% change. |
"Actives" are persons who purchased products directly from the company during the previous three months. |
||
"Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements. |
Operational Performance
The company's operating margin for the quarter was 13.6 percent, compared to 7.4 percent in the prior-year period. Gross margin for the quarter was 79.2 percent, compared to 73.3 percent in the prior-year quarter. Comparisons for both gross and operating margins were impacted by the
Outlook
"We are raising our guidance for the year given strong results in the third quarter," said Hunt. "Fourth-quarter promotional activities are focused on driving consumer loyalty.
"Toward the end of the quarter we began deploying funds to repurchase stock, and anticipate that by the end of 2016 we will have utilized the
"We are raising our revenue guidance for the year to
The
About
Founded more than 30 years ago,
Please Note: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, initiatives, sales force, consumers and new product introductions; projections regarding revenue, earnings per share, foreign currency fluctuations, and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
- any failure of current or planned initiatives or products to generate interest among our sales force and customers and generate sponsoring and selling activities on a sustained basis;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- risk that direct selling laws and regulations in any of our markets, including
the United States andChina , may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events; - risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if we over-forecast demand for a product or change our planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- unpredictable economic conditions and events globally;
- any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of
the United States and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and - continued competitive pressures in the company's markets.
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the
Non-GAAP Financial Measures: Constant-currency revenue growth is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's revenue.
NU SKIN ENTERPRISES, INC. |
|||
Consolidated Statements of Income (Unaudited) |
|||
For the Third Quarters Ended September 30, 2016 and 2015 |
|||
(in thousands, except per share amounts) |
|||
2016 |
2015 |
||
Revenue |
$ 604,162 |
$ 571,308 |
|
Cost of sales |
125,863 |
152,755 |
|
Gross profit |
478,299 |
418,553 |
|
Operating expenses: |
|||
Selling expenses |
255,274 |
240,260 |
|
General and administrative expenses |
140,651 |
135,752 |
|
Total operating expenses |
395,925 |
376,012 |
|
Operating income |
82,374 |
42,541 |
|
Other income, net |
(5,695) |
(14,428) |
|
Income before provision for income taxes |
76,679 |
28,113 |
|
Provision for income taxes |
19,807 |
11,846 |
|
Net income |
$ 56,872 |
$ 16,267 |
|
Net income per share: |
|||
Basic |
$ 1.02 |
$ 0.28 |
|
Diluted |
$ 0.98 |
$ 0.28 |
|
Weighted average common shares outstanding: |
|||
Basic |
55,983 |
57,725 |
|
Diluted |
57,852 |
58,663 |
NU SKIN ENTERPRISES, INC. |
|||
Consolidated Statements of Income (Unaudited) |
|||
For the Nine-Month Periods Ended September 30, 2016 and 2015 |
|||
(in thousands, except per share amounts) |
|||
2016 |
2015 |
||
Revenue |
$ 1,676,468 |
$ 1,674,849 |
|
Cost of sales |
391,937 |
368,073 |
|
Gross profit |
1,284,531 |
1,306,776 |
|
Operating expenses: |
|||
Selling expenses |
699,196 |
713,714 |
|
General and administrative expenses |
415,014 |
410,074 |
|
Total operating expenses |
1,114,210 |
1,123,788 |
|
Operating income |
170,321 |
182,988 |
|
Other (expense), net |
(19,618) |
(29,454) |
|
Income before provision for income taxes |
150,703 |
153,534 |
|
Provision for income taxes |
45,802 |
56,328 |
|
Net income |
$ 104,901 |
$ 97,206 |
|
Net income per share: |
|||
Basic |
$ 1.87 |
$ 1.66 |
|
Diluted |
$ 1.85 |
$ 1.63 |
|
Weighted average common shares outstanding: |
|||
Basic |
55,963 |
58,403 |
|
Diluted |
56,586 |
59,565 |
NU SKIN ENTERPRISES, INC. |
|||
Consolidated Balance Sheets (Unaudited) |
|||
(in thousands) |
|||
September 30, 2016 |
December 31, 2015 |
||
ASSETS |
|||
Current assets: |
|||
Cash and cash equivalents |
$ 516,994 |
$ 289,354 |
|
Current investments |
15,603 |
14,371 |
|
Accounts receivable |
35,985 |
35,464 |
|
Inventories, net |
253,350 |
265,256 |
|
Prepaid expenses and other |
160,537 |
101,947 |
|
982,469 |
706,392 |
||
Property and equipment, net |
451,571 |
454,537 |
|
Goodwill |
114,954 |
112,446 |
|
Other intangible assets, net |
65,408 |
67,009 |
|
Other assets |
137,413 |
165,459 |
|
Total assets |
$ 1,751,815 |
$ 1,505,843 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Current liabilities: |
|||
Accounts payable |
$ 40,490 |
$ 28,832 |
|
Accrued expenses |
337,562 |
310,916 |
|
Current portion of long-term debt |
73,328 |
67,849 |
|
451,380 |
407,597 |
||
Long-term debt |
356,298 |
181,745 |
|
Other liabilities |
89,726 |
90,880 |
|
Total liabilities |
897,404 |
680,222 |
|
Stockholders' equity: |
|||
Class A common stock |
91 |
91 |
|
Additional paid-in capital |
431,563 |
419,921 |
|
Treasury stock, at cost |
(1,047,975) |
(1,017,063) |
|
Accumulated other comprehensive loss |
(68,523) |
(71,269) |
|
Retained earnings |
1,539,255 |
1,493,941 |
|
854,411 |
825,621 |
||
Total liabilities and stockholders' equity |
$ 1,751,815 |
$ 1,505,843 |
Logo - http://photos.prnewswire.com/prnh/20150316/182144LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-third-quarter-2016-results-300357201.html
SOURCE
Investors -- Scott Pond (801) 345-2657, spond@nuskin.com, Media -- Kara Schneck (801) 345-2116, kschneck@nuskin.com